Another rival is Sanofi’s long-acting FVIII replacement therapy Altuviiio (efanesoctocog alfa), which also offers once-weekly dosing. Haemophilia B is likely to be the greatest opportunity for ...
Twice-yearly lenacapavir, a long-acting HIV-1 capsid inhibitor, reduced HIV infections by 96% in the Phase III PURPOSE 2 trial while showing superior efficacy over daily Truvada.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback